Epilepsy: Clinical Trials

40 trials for Epilepsy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

40 terminated. 40 Phase 2, 6 Phase 3, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 240Terminated 40
Phase 36Terminated 6
Phase 12Terminated 2

Follow Epilepsy: new trials by email Literature Review of Epilepsy trials Research Report on Epilepsy

Trials (filtered) newest first · largest first

All 40 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
BHV-7000, Placebo - Generalized Epilepsy
Phase 2 / Phase 3TerminatedBiohaven Therapeutics Ltd.272024-06-202026-03-24
Study of EQU-001 for Uncontrolled Focal Onset Seizures
EQU-001, Matching Placebo - Focal Onset Seizures
Phase 2TerminatedEquilibre Biopharmaceuticals B.V.272022-12-272023-12-21
Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures
NBI-921352 - Focal Onset Seizure, Focal Onset Epilepsy
Phase 2TerminatedNeurocrine Biosciences822022-11-092024-04-12
Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE
NBI-921352 - SCN8A Developmental and Epileptic Encephalopathy Syndrome
Phase 2TerminatedNeurocrine Biosciences82022-07-122026-11-13
Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep
NBI-827104 - Epileptic Encephalopathy, Continuous Spike and Wave During Sleep
Phase 2TerminatedNeurocrine Biosciences192022-06-072026-02-13
Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)
NBI-921352, Placebo - SCN8A Developmental and Epileptic Encephalopathy Syndrome
Phase 2TerminatedNeurocrine Biosciences82022-01-312025-10-16
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures
Lacosamide intravenous, Lacosamide oral, Active Comparator - Electroencephalographic Neonatal Seizures, Epilepsy
Phase 2TerminatedUCB Biopharma SRL292021-03-312025-10-03
Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF Infusion
Valproic Acid delivered to ICV - Focal Epilepsy
Phase 1 / Phase 2TerminatedCerebral Therapeutics LLC202021-01-012024-03-13
An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
CVL-865 - Seizures
Phase 2TerminatedAbbVie1052020-12-082025-12-11
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
Vatiquinone, Placebo - Mitochondrial Diseases, Drug Resistant Epilepsy
Phase 2 / Phase 3TerminatedPTC Therapeutics682020-09-282026-03-31
Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization
ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC), Placebo delivery via an implantable pump and a cranial port and dual lumen catheter (CIC) - Refractory Epilepsy
Phase 2TerminatedCerebral Therapeutics LLC302020-08-212024-03-13
A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients
JBPOS0101 - Refractory Infantile Spasms
Phase 2TerminatedBio-Pharm Solutions Co., Ltd.162020-04-152024-08-22
Flunarizine for Treatment Resistant Absence Epilepsy
Flunarizine Hydrochloride - Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Phase 2TerminatedUniversity of British Columbia92019-09-202023-12-01
A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy
Placebo, E2082 - Photosensitive Epilepsy
Phase 2TerminatedEisai Inc.82018-10-312020-09-28
Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy
Padsevonil - Drug-Resistant Epilepsy, Focal-Onset Seizures
Phase 2TerminatedUCB Biopharma SRL4062018-08-272021-12-29
A Study to Evaluate the Pharmacodynamic Activity of E2730 in Adult Participants With Photosensitive Epilepsy
Placebo, E2730 - Photosensitive Epilepsy
Phase 2TerminatedEisai Inc.62018-07-272022-05-04
A Study of Soticlestat in Adults and Children With Rare Epilepsies
Soticlestat - Epilepsy, Dravet Syndrome (DS)
Phase 2TerminatedTakeda1562018-07-192026-09-04
Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures
Cannabidiol Oral Solution - Childhood Absence Epilepsy
Phase 2TerminatedRadius Pharmaceuticals, Inc.112018-02-202023-06-18
Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures
Cannabidiol Oral Solution - Childhood Absence Epilepsy
Phase 2TerminatedRadius Pharmaceuticals, Inc.202017-12-292023-07-21
A Phase 2 Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS)
Radiprodil - Infantile Spasms (IS)
Phase 2TerminatedUCB Biopharma S.P.R.L.32017-12-042019-09-17

Showing 20 of 40. Sign in to see all of them.

Narrower conditions

Seizures (14)  ·  Drug Resistant Epilepsy (7)  ·  Epilepsies, Partial (7)  ·  Epilepsy, Absence (4)  ·  Spasms, Infantile (4)  ·  Epilepsies, Myoclonic (3)  ·  Epilepsy, Reflex (2)  ·  Epilepsy, Temporal Lobe (2)  ·  Leigh Disease (2)  ·  Lennox Gastaut Syndrome (2)  ·  Mitochondrial Diseases (2)  ·  Myoclonic Epilepsy, Juvenile (2)  ·  Status Epilepticus (2)  ·  Acidosis, Lactic (1)

Broader conditions

Brain Diseases (40)  ·  Central Nervous System Diseases (40)  ·  Nervous System Diseases (40)  ·  Neurologic Manifestations (17)  ·  Pathological Conditions, Signs and Symptoms (17)  ·  Signs and Symptoms (17)  ·  Epileptic Syndromes (15)  ·  Epilepsy, Generalized (11)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4)  ·  Genetic Diseases, Inborn (4)  ·  Epilepsies, Myoclonic (3)  ·  Brain Diseases, Metabolic (2)  ·  Brain Diseases, Metabolic, Inborn (2)  ·  Carbohydrate Metabolism, Inborn Errors (2)

Interventions

Cannabidiol (4)  ·  Diazepam (2)  ·  Lacosamide (2)  ·  Acetazolamide (1)  ·  Buspirone (1)  ·  Carvedilol (1)  ·  Cysteamine (1)  ·  Fish Oils (1)  ·  Flunarizine (1)  ·  Immunoglobulins, Intravenous (1)  ·  PF-06372865 (1)  ·  Safflower Oil (1)  ·  alpha-tocotrienol quinone (1)  ·  ezogabine (1)  ·  ganaxolone (1)

Sponsors

Neurocrine Biosciences (4)  ·  UCB Biopharma SRL (3)  ·  Acorda Therapeutics (2)  ·  Cerebral Therapeutics LLC (2)  ·  Eisai Inc. (2)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (2)  ·  Radius Pharmaceuticals, Inc. (2)  ·  AbbVie (1)  ·  Addex Pharma S.A. (1)  ·  Amgen (1)  ·  Bio-Pharm Solutions Co., Ltd. (1)  ·  Biohaven Therapeutics Ltd. (1)  ·  Columbia University (1)  ·  Emory University (1)  ·  Equilibre Biopharmaceuticals B.V. (1)

Countries

United States (29)  ·  Australia (8)  ·  Spain (8)  ·  Canada (7)  ·  France (7)  ·  United Kingdom (6)  ·  Belgium (5)  ·  Germany (5)  ·  Poland (5)  ·  Israel (4)  ·  Italy (4)  ·  Hungary (3)  ·  Austria (2)  ·  Bulgaria (2)  ·  Croatia (2)

Top investigators

Ahmed Elkashef, MD (2)  ·  William H Theodore, M.D. (2)  ·  Beverly S Wical, MD (1)  ·  Charles M. Epstein, M.D. (1)  ·  Derek Chong, MD, MSc (1)  ·  Hee Jin Kim (1)  ·  Katherine C. Nickels, M.D. (1)  ·  Lee Min Jae (1)  ·  Mac Burnham, PhD (1)

Results publications

PMID 35965432

NIH funding

2008 (1), 2015 (1), 2016 (1), 2017 (1), 2018 (1), 2019 (1), 2023 (1)